Literature DB >> 21840066

Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy.

Daniel M Harrison1, Scott D Newsome, Richard L Skolasky, Justin C McArthur, Avindra Nath.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is typically associated with minimal inflammation; however, patients may develop an inflammatory response due to immune reconstitution (IRIS). The authors aimed to determine if characteristics and outcomes of PML are altered in those with IRIS. A retrospective records review was performed on 87 patients diagnosed with PML at Johns Hopkins, 27 of which had a syndrome consistent with IRIS. Gadolinium enhancement on MRI occurred in 44.4% of cases of PML-IRIS versus 5.1% in PML (p<0.05), and thus had low diagnostic sensitivity and specificity. In HIV+ cases, CD4 counts were lower in those who later developed IRIS (mean 34.8 vs. 71.7, p<0.05) and was predictive of the development of IRIS (p<0.05). Improved prognosis was seen with higher cerebrospinal fluid (CSF) white blood cell counts and protein levels, but not for gadolinium enhancement and there were no differences in survival for PML versus PML-IRIS.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840066      PMCID: PMC4916968          DOI: 10.1016/j.jneuroim.2011.07.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  30 in total

1.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.

Authors:  B L Padgett; D L Walker; G M ZuRhein; R J Eckroade; B H Dessel
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

4.  Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.

Authors:  Aurélie Vendrely; Boris Bienvenu; Jacques Gasnault; Jean Baptiste Thiebault; Dominique Salmon; Françoise Gray
Journal:  Acta Neuropathol       Date:  2005-03-01       Impact factor: 17.088

5.  Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier.

Authors:  Donald Wong; Katerina Dorovini-Zis; Steven R Vincent
Journal:  Exp Neurol       Date:  2004-12       Impact factor: 5.330

6.  Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients.

Authors:  DeRen Huang; Michael Cossoy; Meizhang Li; Dean Choi; Alan Taege; Susan M Staugaitis; Susan Rehm; Richard M Ransohoff
Journal:  Ann Neurol       Date:  2007-07       Impact factor: 10.422

7.  Progressive multifocal leukoencephalopathy in patients with HIV infection.

Authors:  J R Berger; L Pall; D Lanska; M Whiteman
Journal:  J Neurovirol       Date:  1998-02       Impact factor: 2.643

8.  Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.

Authors:  Samuel A Shelburne; Fehmida Visnegarwala; Jorge Darcourt; Edward A Graviss; Thomas P Giordano; A Clinton White; Richard J Hamill
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

9.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

10.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

View more
  13 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

2.  Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome.

Authors:  Michael N Khoury; Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Igor J Koralnik
Journal:  Brain       Date:  2013-10-01       Impact factor: 13.501

3.  Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment.

Authors:  C C Chang; V Sheikh; I Sereti; M A French
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 4.  Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.

Authors:  Lokesh Shahani; Minal Shah; Shahriar Tavakoli-Tabasi
Journal:  BMJ Case Rep       Date:  2015-06-10

Review 5.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 6.  The immune reconstitution inflammatory syndrome related to HIV co-infections: a review.

Authors:  D Huis in 't Veld; H-Y Sun; C-C Hung; R Colebunders
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-02       Impact factor: 3.267

7.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

8.  Metabolic profile of PML lesions in patients with and without IRIS: an observational study.

Authors:  Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

9.  PML-IRIS in a patient treated with brentuximab.

Authors:  Gloria von Geldern; Carlos A Pardo; Peter A Calabresi; Scott D Newsome
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

10.  Central nervous system immune reconstitution inflammatory syndrome.

Authors:  Nathan Bahr; David R Boulware; Suzaan Marais; James Scriven; Robert J Wilkinson; Graeme Meintjes
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.